AD80 HAS HIGHER POTENCY COMPARED TO CLINICALLY USED FLT3 INHIBITORS IN FLT3-ITD AML CELLS
Objectives: Acute myeloid leukemia (AML) with fms-like tyrosine kinase 3 (FLT3) mutations account for around 30% of all AML cases. FLT3 is a transmembrane receptor with important roles for hematological cells. The mutations will cause overactivation of signaling pathways such as PI3K, RAS, and STAT5...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-10-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137923006338 |